BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10494176)

  • 21. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation.
    de la Rubia J; Saavedra S; Sanz GF; Martín G; Moscardó F; Martínez J; Jarque I; Jiménez C; Sanz MA
    Bone Marrow Transplant; 2001 Jan; 27(1):21-5. PubMed ID: 11244434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Hino M; Akahori M; Terada Y; Yamane T; Ohta K; Hayashi T; Tsumura K
    Am J Hematol; 2004 May; 76(1):1-7. PubMed ID: 15114589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
    Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematological toxicity of salvage treatment after high-dose chemotherapy and conventional chemotherapy of ovarian cancer.
    Vuento MH; Salmi TA; Remes KJ; Grénman SE
    Anticancer Res; 2002; 22(2B):1151-5. PubMed ID: 12168916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report.
    Berger M; Ferrero I; Vassallo E; Gastaldo L; Carraro F; Biasin E; Madon E; Fagioli F
    Pediatr Hematol Oncol; 2005; 22(7):597-608. PubMed ID: 16166053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.
    Ke X; Yang Y; Zhao X; Wang L
    Chin Med J (Engl); 2001 Feb; 114(2):196-9. PubMed ID: 11780206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
    Kozuka T; Kiura K; Katayama H; Fujii N; Ishimaru F; Ikeda K; Ueoka H; Hamasaki S; Yoshino T; Kashihara Y; Date H; Tanimoto M; Harada M
    Anticancer Res; 2002; 22(5):2939-44. PubMed ID: 12530021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
    Grodman H; Wolfe L; Kretschmar C
    Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.